Janney Montgomery Scott LLC purchased a new stake in Nightstar Therapeutics PLC (NASDAQ:NITE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,000 shares of the company’s stock, valued at approximately $204,000.
A number of other hedge funds also recently made changes to their positions in NITE. Bank of America Corp DE acquired a new position in shares of Nightstar Therapeutics during the second quarter worth about $132,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Nightstar Therapeutics in the third quarter valued at approximately $169,000. Stanley Laman Group Ltd. bought a new stake in Nightstar Therapeutics in the second quarter valued at approximately $195,000. Millennium Management LLC acquired a new stake in Nightstar Therapeutics during the first quarter worth approximately $507,000. Finally, Woodford Investment Management Ltd acquired a new stake in Nightstar Therapeutics during the second quarter worth approximately $5,024,000. 37.84% of the stock is currently owned by institutional investors and hedge funds.
NITE stock opened at $14.52 on Thursday. Nightstar Therapeutics PLC has a 1 year low of $9.59 and a 1 year high of $29.55. The stock has a market capitalization of $408.01 million, a P/E ratio of -8.91 and a beta of 3.90.
Nightstar Therapeutics (NASDAQ:NITE) last issued its earnings results on Tuesday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.13. On average, analysts anticipate that Nightstar Therapeutics PLC will post -1.45 EPS for the current year.
A number of equities research analysts have weighed in on NITE shares. BMO Capital Markets set a $41.00 target price on Nightstar Therapeutics and gave the company a “buy” rating in a report on Monday, September 24th. Zacks Investment Research lowered Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Nightstar Therapeutics in a research report on Tuesday, September 25th. Mizuho reaffirmed a “buy” rating and issued a $24.00 target price on shares of Nightstar Therapeutics in a research report on Tuesday, September 25th. Finally, Janney Montgomery Scott initiated coverage on Nightstar Therapeutics in a research note on Wednesday, August 22nd. They set a “buy” rating and a $34.00 price target for the company. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $34.43.
WARNING: “Janney Montgomery Scott LLC Invests $204,000 in Nightstar Therapeutics PLC (NITE) Stock” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/06/janney-montgomery-scott-llc-invests-204000-in-nightstar-therapeutics-plc-nite-stock.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Featured Story: Exchange-Traded Funds (ETFs)
Want to see what other hedge funds are holding NITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nightstar Therapeutics PLC (NASDAQ:NITE).
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.